

Elisa Vegezzi

Project title: *Genetic modifiers in hereditary ATTR amyloidosis*

Duration	6 months
Short Bio	<p>I am a neurologist actively committed in the field of neurogenetics, with a particular interest in peripheral nerve disorders, especially in hereditary neuropathies.</p> <p>My Ph.D. program has been focused on the evaluation by quantitative muscle MRI of novel outcome measures in hereditary ATTR amyloidosis and on the clinical phenotyping and screening by whole-exome sequencing of a cohort of patients with suspected inherited neuropathies/ataxias/spastic paraparesis, trying to address the molecular diagnosis.</p> <p>More recently, I have started dedicating to the identification of genetic modifiers of age of onset and clinical phenotype of hereditary ATTR amyloidosis, stemming from a collaborative genome-wide association study (GWAS) project involving more than 50 Centres across the globe with a proven expertise on this rare condition, which has been the topic of my ERN Research Mobility Fellowship</p>
Home Institution	Mondino Foundation IRCCS (Pavia)
Host institution	UCL Queen Square Institute of Neurology (London)
Project description	<p>The project is aimed at identifying loci harboring genetic variations which modify age of onset, penetrance, phenotype, clinical severity, progression, and response to anti-amyloidogenic treatments in hereditary ATTR amyloidosis through a GWAS.</p> <p>Also, it will characterize by long-read sequencing (<i>PacBio</i> and <i>Oxford Nanopore</i>) the <i>TTR</i>-containing region across different populations and ethnicities to phase nearby variants (<i>cis</i> or <i>trans</i>) associated with the <i>TTR</i> mutation itself which define different intragenic haplotypes</p>
Personal statement	<p>This exchange gave me the opportunity to deepen my knowledge of GWA studies and data analysis, and to gather specific expertise on long-read sequencing technique (<i>PacBio</i> and <i>Oxford Nanopore</i>), which, beyond the specific case of hereditary ATTR amyloidosis here reported, could be also applied to other inherited neurological disorders to better explain their genetic bases, or even to acquired conditions.</p> <p>Also, since the host Institution (UCL Queen Square Institute of Neurology) is member of both EURO-RND and EURO-NMD and has proven expertise on GWA studies, the development of the project on hereditary ATTR amyloidosis in this context, has provided so far</p>

In collaboration with :



	seminal tasks/methodology to run similar research projects also for different rare neurological disorders
--	---

In collaboration with :



The EJP RD initiative has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°825575